Biotech · Public company · South San Francisco, CA, US
Rigel Pharmaceuticals Inc
Ticker RIGL · SEC CIK 0001034842
Track this companyFree. Adds Rigel Pharmaceuticals Inc to your Dealase workspace and tells you when its record changes.
Clinical trials2110 recruiting or active
Pipeline programs11From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline11
- FostamatinibPhase 3 · Covid19ClinicalTrials.gov · fetched Nov 12, 2026
- Fostamatinib disodiumPhase 3 · Warm Antibody Autoimmune Hemolytic AnemiaClinicalTrials.gov · fetched Nov 12, 2026
- Fostamatinib DisodiumPhase 3 · Immune Thrombocytopenic PurpuraClinicalTrials.gov · fetched Nov 12, 2026
- Fostamatinib 100 mgPhase 2 · IGA NephropathyClinicalTrials.gov · fetched Nov 12, 2026
- Fostamatinib 150 mgPhase 2 · IGA NephropathyClinicalTrials.gov · fetched Nov 12, 2026
- Fostamatinib 150 mg bidPhase 2 · Warm Antibody Autoimmune Hemolytic AnemiaClinicalTrials.gov · fetched Nov 12, 2026
- Olutasidenib + TMZPhase 2 · High Grade GliomaClinicalTrials.gov · fetched Nov 12, 2026
- R906289 Monosodium (R289 Na)Phase 2 · Low Risk Myelodysplastic SyndromesClinicalTrials.gov · fetched Nov 12, 2026
- CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe SubstratesAML (Acute Myeloid Leukemia)ClinicalTrials.gov · fetched Nov 12, 2026
- FostamatinibITPClinicalTrials.gov · fetched Nov 12, 2026
- OlutasidenibAML (Acute Myeloid Leukemia)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials21
- Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received VenetoclaxPHASE2 · RECRUITING · started Nov 1, 2026ClinicalTrials.gov NCT07471841 · fetched Nov 12, 2026
- Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction ChemotherapyPHASE2 · RECRUITING · started Mar 31, 2026ClinicalTrials.gov NCT06782542 · fetched Nov 12, 2026
- Olutasidenib DDI Study in Patients With IDH1 Mutation Positive MalignanciesPHASE4 · RECRUITING · started Feb 23, 2026ClinicalTrials.gov NCT07486713 · fetched Nov 12, 2026
- Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHDPHASE1 · RECRUITING · started Oct 29, 2025ClinicalTrials.gov NCT06233110 · fetched Nov 12, 2026
- Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway MutationsPHASE2 · RECRUITING · started Sep 12, 2025ClinicalTrials.gov NCT07032727 · fetched Nov 12, 2026
- Study of Olutasidenib and Temozolomide in HGGPHASE2 · RECRUITING · started Feb 1, 2025ClinicalTrials.gov NCT06161974 · fetched Nov 12, 2026
- A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.PHASE2 · RECRUITING · started Dec 10, 2024ClinicalTrials.gov NCT06566742 · fetched Nov 12, 2026
- Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic CancerPHASE1 · RECRUITING · started Dec 5, 2024ClinicalTrials.gov NCT06639724 · fetched Nov 12, 2026
- An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid ArthritisPHASE2 · COMPLETED · started May 23, 2023ClinicalTrials.gov NCT05848258 · fetched Nov 12, 2026
- Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)PHASE1_PHASE2 · RECRUITING · started Sep 12, 2022ClinicalTrials.gov NCT05308264 · fetched Nov 12, 2026
- Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior TherapyTERMINATED · started May 18, 2021ClinicalTrials.gov NCT04904276 · fetched Nov 12, 2026
- Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe ThrombocytopeniaPHASE2 · TERMINATED · started May 3, 2021ClinicalTrials.gov NCT04543279 · fetched Nov 12, 2026
- Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 SubjectsPHASE3 · COMPLETED · started Mar 25, 2021ClinicalTrials.gov NCT04629703 · fetched Nov 12, 2026
- A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic AnemiaPHASE3 · ENROLLING_BY_INVITATION · started Oct 30, 2019ClinicalTrials.gov NCT04138927 · fetched Nov 12, 2026
- A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHAPHASE3 · COMPLETED · started Apr 24, 2019ClinicalTrials.gov NCT03764618 · fetched Nov 12, 2026
- Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian CancerPHASE1 · COMPLETED · started Apr 3, 2018ClinicalTrials.gov NCT03246074 · fetched Nov 12, 2026
- A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)PHASE2 · COMPLETED · started Jul 1, 2016ClinicalTrials.gov NCT02612558 · fetched Nov 12, 2026
- A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)PHASE3 · COMPLETED · started Jan 1, 2015ClinicalTrials.gov NCT02076412 · fetched Nov 12, 2026
- Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)PHASE3 · COMPLETED · started Oct 1, 2014ClinicalTrials.gov NCT02077192 · fetched Nov 12, 2026
- Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) NephropathyPHASE2 · COMPLETED · started Oct 1, 2014ClinicalTrials.gov NCT02112838 · fetched Nov 12, 2026
- A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)PHASE3 · COMPLETED · started Jul 14, 2014ClinicalTrials.gov NCT02076399 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 4, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 1, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 17, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 20, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 5, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 21, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 3, 2026 · fetched Nov 12, 2026